Dabomb Protein Biotech Corporation

Dabomb Protein Biotech Corporation

TTPEX:6578
15.90
TWD
-0.10
(-0.62%)
-0.35EPS
1.18BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
30.28
28.08
25.33
19.62
20.78
19.7
18.37
14.49
11.21
5.75
5.06
4.3
5.25
Basic EPS, GAAP
- -
1.08
2.17
2.38
0.98
0.84
0.65
0.22
-1.92
-1.15
-0.85
0.17
-0.96
-0.35
Free Cash Flow per Basic Share
- -
-0.85
4.69
-1.15
-4.28
-4.7
-1.78
-0.15
-11.59
-0.01
-0.19
0.26
-0.29
0.25
Dividend per Share
- -
0.2
0.31
0.97
0.76
0.43
0.71
0.45
0.19
- -
- -
- -
0.17
- -
Book Value per Share
10.9
19.18
20.68
21.63
21.62
21.65
21.2
20.72
20.38
18.4
16.05
16.02
13.75
14.11
Tangible Book Value per Share
10.9
19.15
20.66
21.55
21.55
21.59
21.14
20.68
20.37
18.4
16.04
16.02
13.75
14.11
Basic Weighted Avg Shares
32
26
29
29
29
30
33
33
32
39
67
67
72
72
Sales/Revenue/Turnover
- -
802
805
727
562
623
647
605
471
434
384
338
309
377
Operating Margin (%)
- -
3.66
10.74
11.48
7.3
5.02
6.05
2.54
-13.55
-14.41
-7.79
-0.54
-9.11
1.17
Depreciation Expense
- -
12
12
10
12
11
17
26
26
27
22
14
41
29
Net Income, GAAP
- -
29
62
68
28
25
21
7
-62
-45
-57
12
-69
-25
Effective Tax Rate (%)
- -
18.86
18.83
18.15
26.43
25.03
33.16
38.15
- -
- -
- -
27.57
- -
- -
Profit Margin (%)
- -
3.57
7.73
9.4
4.98
4.04
3.28
1.19
-13.27
-10.3
-14.83
3.44
-22.42
-6.69
Working Capital
172
408
468
412
327
189
174
191
179
124
422
475
141
159
LT Debt
44
42
40
38
75
- -
72
84
437
333
86
46
20
8
Total Equity
300
528
593
620
623
711
698
701
674
727
958
1,089
989
1,015
Return on Invested Capital (%)
- -
3.95
10.23
9.54
3.92
2.95
3.16
1.02
- -
- -
- -
-0.1
- -
- -
Return on Capital (%)
- -
5.51
9.56
9.95
3.88
3.36
2.68
0.95
- -
- -
- -
1.17
- -
- -
Return on Common Equity (%)
- -
6.92
11.09
11.27
4.51
3.77
3.01
1.03
-9.08
-6.37
-6.77
1.14
-6.67
-2.46

Capital Structure

TWD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
32
59
111
LT Borrowings
15
10
5
LT Finance Leases
- -
- -
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
72
72
72
Market Capitalization
1,266
1,191
1,183

Working Capital

TWD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
216
256
313
Cash, Cash Equivalents & STI
136
169
221
Accounts Receivable, Net
48
52
46
Inventories
26
30
36
Total Current Liabilities
69
98
154
Payables & Accruals
- -
- -
- -
ST Debt
32
59
111
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.81%
8.07%
-9.18%
Free Cash Flow
968.57%
1,935.07%
-222.09%
Net Income, GAAP
-192.64%
-357.04%
-695.84%
Sales/Revenue/Turnover
-8.61%
-12.4%
-8.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
101
98
57
82
338
2025
69
91
- -
81
309
2026
82
107
106
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.08
-0.02
0.02
0.17
2025
0.03
-0.21
- -
-0.62
-0.96
2026
0.08
0.13
0.06
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.17
2026
- -
- -
- -
- -
- -

Company Description

CEO
Yu Fen Liu
Full Time Employees
47
Sector
Consumer non-durables
Industry
Food: major diversified
Address
No.52, Gongye 3rd Road Tainan TQ Taiwan 709
IPO Date
Sep 18, 2018
Business
DaBomb Protein Biotech Corp. (6578.TWO), headquartered in Tainan City, Taiwan, and founded in 2001, develops and manufactures plant-based proteins, antibiotic alternatives, and related biotech products for the animal health, aquaculture, livestock, pet care, and agricultural sectors. The company produces core offerings including hydrolyzed soya peptides such as DaBomb-P (Aqua) for aquaculture feed and DaBomb-P (Livestock) for animal nutrition; antibiotic alternatives like DBT-100 HT, DBT-100 LS, and postbiotic-based ProbioSyntec solutions leveraging innovative fermentation technology; functional peptides and natural L-lactate as food additives; pet care items comprising Liqui-TIDE bandages; and plant biostimulants like DaBomb Ti featuring fermented peptides and 18 amino acids for crops, fruit trees, vegetables, and turf. It operates factories in Taiwan, including sites in Tainan and Pingtung Agricultural Biotechnology Park, and in Zhangzhou, Fujian, China, exporting primarily to Southeast Asia, Northeast Asia, and other international markets with an annual production capacity exceeding 40,000 tons. Recent developments include its 2023 renaming from DaBomb Protein Corp. to DaBomb Protein Biotech Corp., attainment of FAMI-QS Bioprocess and Mixing certifications, ongoing ProbioSyntec development since 2020, a 2024 CDMO partnership with a US feed enzyme company for protease production, and groundbreaking in late 2024 on a new Tainan fermentation facility set for 2025 operations to expand capacities.